Investors & Media
Company OverviewView All
LyGenesis’s cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. Our pipeline of therapies target a variety of unmet needs, including end stage liver disease, Type 1 diabetes, end stage renal disease, aging, and autoimmune disorder.
iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression
The joint research collaboration will evaluate the potential of iTOL-201, the product candidate in development using iTolerance’s SA FasL microgel immune tolerance platform (iTOL-100) combined with LyGenesis’ liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the need or immune suppression.Read More
LyGenesis Adds Inborn Errors of Metabolism, Orphan Pediatric Indications with Large Unmet Needs, to its Drug Development Pipeline
January 10, 2022 - Novel approach first aims to treat pediatric patients with Maple Syrup Urine Disease
LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology
August 27, 2021 - Successful preclinical studies solidify the foundation for its first human clinical trial of a cell-based therapy to regenerate ectopic organs in lymph nodes
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
July 23, 2021 - LyGenesis will continue to advance its clinical-stage allogeneic cell therapy for patients with end stage liver disease, and advance its pipeline of preclinical cell therapies enabling pancreas, thymus, and kidney regeneration.
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
March 2, 2021 - Merger would create a clinical-stage cell therapy company
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing
December 30, 2020 - LyGenesis, Inc. announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application.
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology
October 21, 2019 - Funds will support a Phase 2a clinical trial for patients with end stage liver disease in 2020